Wilber Huang's Biography

• Home
• |
• Registration
• |
• Submissions
  • Submission Guidelines
  • Submissions
• |
• Agenda
• |
• Exhibition
• |
• Venue
• |
• Media
• |
• Short Courses
  • Training Courses
• |

Microfluidic Capture, Identification, and Isolation of EMT-transformed Cancer Stem Cells

Thursday, 7 April 2016 at 14:30

Add to Calendar ▼2016-04-07 14:30:002016-04-07 15:30:00Europe/LondonMicrofluidic Capture, Identification, and Isolation of EMT-transformed Cancer Stem CellsExosomes and Liquid Biopsies Asia 2016 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com

Persistence of cancer stem cells (CSCs) prevents effective therapy of tumors. Epithelial mesenchymal transition (EMT) of CSCs provides the engine of plasticity for breaking CSC dormancy causing tumor relapse and metastasis.  Current isolation of CSCs relies on magnetic beads-based, antibody selection to deplete the abundant CD45 cell fraction. This conventional negative enrichment is handicapped by lower cell capture and recovery, and without retrieval method for downstream cell culture.  Moreover, the detection of CSCs has been hampered by the lack of cancer- and mesenchymal-specific markers. Recent identification of cancer-specific EMT markers such as cytoplasmic Plastin-3 (PLS3) and Cell Surface Vimentin (CSV) has opened up this bottleneck for studies of EMT-transformed CSCs.  Both markers are not expressed by normal cells in the circulation.  Leveraging Abnova’s vertically integrated CytoQuest™ CR platform, we report the first microfluidic-based, antibody capture, identification, and retrieval of EMT-transformed CSCs. Such open platform should accelerate the research and clinical applications of EMT-transformed CSC for improved diagnosis and therapy for cancer patients.